HAE
Acute attacks, which may occur many hours after a procedure, may be treated with C1-INH; icatibant, a bradykinin B2-receptor antagonist; or ecallantide, a kallikrein inhibitor, all of which have been shown to reduce the duration and severity of HAE attacks.
Acute attacks, which may occur many hours after a procedure, may be treated with <span class="gene" id="23866957-9-81-87">C1-INH</span>; icatibant, a bradykinin B2-receptor antagonist; or ecallantide, a kallikrein inhibitor, all of which have been shown to reduce the duration and severity of <span class="disease" id="23866957-9-245-248">HAE</span> attacks.